TT 103MH - Thrombotargets Corp

Biotecnología
Deep vein thrombosis symptoms
Vein thrombosis
Hemophilia treatment
Superficial thrombosis
Trombosis treatment

[ Cerrar ]

Discovery & Pipeline

Thrombotargets has developed and adapted to High Throughput Screening, a new family of biological assays capable to quantify simultaneously clot formation and clot lysis (HemostaScreen), total antioxidant capacity (OxidantScreen) and low-density lipoprotein modification (AtheroScreen). With these proven proprietary new HTS Platforms (), Thrombotargets is creating a continuously novel and promising pipeline of drug candidates.

TT 103MH

TT-103MH is a proprietary targeted antihemorrhagic human recombinant protein that induces a fast, efficient and stable blood coagulation.

Procoagulant disorders

TT-103MH is the unique procoagulant drug under development able to stop bleeding caused by heparin treatment. Contact us and know more about how you can find solution for procoagulant disorders with TT-103MH.

Antihemorrhagic drug

Know the TT-103MH by Thrombotargets. The antihemorrhagic drug that Thrombotargets' team is developing for bleeding treatments. Revolutionary topical administration. Know the characteristic of this antihemorrhagic drug.

Superficial thrombosis

Thrombotargets is the biotech company that develops new medicines (recombinant DNA, molecular biology and small molecule drug technologies) for superficial thrombosis and other kinds of coagulation diseases.

Thrombotargets is developing TT- 103MH, a novel and significantly radical approach for the treatment of bleeding disorders. Using a topical formulation TT-103MH, will be effective in treating:

• Healthy subjects
• Haemophilic patients
• Inherited and acquired coagulation and platelet disorders
• Haemorrhages induced by anticoagulant and antiplatelet drugs.